co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More
CNBC-TV18‘s Archana Shukla reports that the pharma sector‘s fortunes in the January-March quarter were dictated by the US market while the sector's earnings were mixed.
SBI Cap Securities‘ Vivek Kumar continues to be bullish on Ranbaxy Laboratories despite its poor first quarter earnings; as against other brokerage houses like Quant Capital and Angel Broking which are advising to stay away from the stock.
Ranbaxy's first quarter net profit is seen at Rs 173 crore, compared with a Rs 1,246 crore profit in the year ago quarter, according to a CNBC-TV18 poll. The results are not really comparable since it got a boost from launch of generic Lipitor last year.
Bino Pathiparampil of IIFL, says that stock like Sun Pharma has been beating estimates for last eight quarters and the same performance is likely to continue in this quarter. Ranbaxy‘s business has been worsening over the last 2-3 quarters and one can‘t expect major improvement to happen in the base business.
Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).
Ranbaxy shares tumbled 4 percent on Wednesday morning, extending Tuesday's losses on a surprise fourth quarter loss on the back of falling sales and costs related to the recall of its cholesterol lowering drug in the US market.
In an interview to CNBC-TV18, Vivek Kumar, SBI Cap Securities spoke about Ranbaxy's results and his outlook going forward.
Pharmaceutical firm Ranbaxy Laboratories is expected to report a profit after tax of Rs 194 crore in the three month period ended September 2012 as against loss of Rs 464 crore in a year ago period, according to CNBC-TV18 poll.
Pharmaceutical firm Ranbaxy Laboratories' revenues are seen going up by 27 percent year-on-year to Rs 2,656 crore in the third quarter of current calendar year.
Pharmaceutical company Ranbaxy Labs' revenues are seen going up by 30% YoY to Rs 2,727 crore and earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to go up by 117% YoY to Rs 395 crore in the April-June quarter.
Pharmaceutical company Ranbaxy Labs is set to declare its second quarter numbers for the calendar year 2012 on Thursday. Analysts on an average expect the profit after tax is likely to be at Rs 235 crore as against Rs 243 crore in a year ago period and Rs 1,247 crore in the previous quarter.
In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.
Pharma major Ranbaxy on Wednesday beat street estimates with a four-fold year-on-year jump in first quarter net profit at Rs 1,247 crore. However, many analysts were unimpressed on the results, which were boosted mainly by forex gains and strong sales of its copy of cholesterol lowering drug Lipitor.
Pharma major Ranbaxy on Wednesday beat street estimates with a four-fold year-on-year increase in first quarter net profit at Rs 1,247 crore, helped by strong sales including that of its cholesterol lowering drug Atorvastatin in the US market, and forex gains.
Pharmaceutical firm Ranbaxy Laboratories is expected to report a growth of 34% year-on-year in its profit after tax at Rs 408 crore for the first quarter of CY12.
According to the report on earnings preview for the quarter ended March 2012, KR Choksey expects the pharma sector will show strong performance in the domestic pharmaceuticals market mainly due to recovery in Indian pharma market.
Ranbaxy's fourth quarter earnings got a mixed response from the street on Friday. The stock rose about 1% in early trade but slipped below Thursday's close soon after. Analysts too were divided, although most agree that resolution of all issues with the US Food and Drug Administration is key for Ranbaxy going ahead.
Ranbaxy Laboratories is to announce its Q4CY11. According to CNBC-TV18 estimates, the company's Q4CY11 revenues are seen up 48% to Rs 3156 crore versus Rs 2129 crore.
Ranbaxy Laboratories is to announce its Q4CY11. According to CNBC-TV18 estimates, the company's Q4CY11 revenues are seen up 48% to Rs 3156 crore versus Rs 2129 crore.
In an interview to CNBC-TV18, Praful Borah of Nirmal Bang Institutional Equities speak about Glenmark, Divi's results and gives his outlook going forward.
Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.
KRChoksey has come with its December quarterly earning estimates for Pharma sector. According to the research firm, Q3FY12 is expected to be a strong quarter in terms of top-line growth mainly due to improved performance in the Indian pharmaceutical market, launch of limited competitive products in the US market & rupee depreciation.
After a sluggish first quarter, pharma universe reported some encouraging numbers in the second quarter. This is with some support from stable growth in certain geographies but inflationary pressures taking a test on the other hand report CNBC-TV18's Archana Shukla.
Pharmaceutical firm Ranbaxy Labs is expected to report a profit after tax of Rs 140 crore in the third quarter of 2011 as against Rs 308 crore in a year ago period.
KR Choksey has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Ranbaxy September quarter net sales are expected to go up by 8% at Rs 2043 crore, year-on-year, (YoY) basis.
